Lead paragraph
The past nine months have delivered a distinct re-rating for capital‑intensive, molecule‑centric industries relative to the service economy. Chemical and materials producers have outperformed broad equity benchmarks as investors shift from intangible, service‑based cash flows toward businesses with tangible assets and secured supply chains; according to the Financial Times (27 Mar 2026), the European chemicals cohort rose roughly 18% year‑to‑date through late March 2026 versus a single‑digit gain for the STOXX Europe 600 over the same period (FT, 27 Mar 2026). This rotation — picked up by market participants as a reversal of the so‑called Halo trade — is supported by concrete macro developments: global manufacturing capital expenditure increased in 2025 by an estimated 8% to around $1.05 trillion (OECD, 2025), while semiconductor capex commitments for 2026 are projected to be near $95 billion, up approximately 20% year‑on‑year (World Semiconductor Trade Statistics, 2026). For institutional investors, the data suggest a regime shift in relative returns and factor composition that warrants systematic reappraisal rather than knee‑jerk reallocation.
Context
The macro backdrop entering 2026 has been characterized by two reinforcing forces: policy‑driven reshoring and inflation‑era investment in durable capital. Governments in Europe, North America and parts of Asia have intensified industrial policy measures — subsidies, tax credits and targeted procurement — that raise the expected return on heavy capital investment in chemicals, semiconductors and advanced materials (EU Industrial Strategy updates, 2025–26). That policy wave has shifted risk premia for long‑life assets, compressing required returns for greenfield projects and improving visibility on multi‑year cash flows for incumbent producers. The FT highlighted on 27 March 2026 that capital‑intensive firms are 'taking revenge' on service sector megacap winners by delivering stronger free cash flow growth and expanding balance‑sheet commitments (FT, 27 Mar 2026).
The investor rotation is not uniform across all capital‑intensive sectors. Chemicals and specialty materials have benefited from secular demand tied to electrification, battery chemistry and green hydrogen feedstocks, while legacy bulk producers are more sensitive to commodity cycles. Similarly, semiconductor manufacturers show a bifurcation: logic fabs and materials suppliers whose revenues are underpinned by long lead‑time contracts have seen stronger re‑ratings than foundry players exposed to spot device cycles. The distinction matters for portfolio construction: a generic bet on 'capex' will capture dispersion that can materially change risk/return profiles relative to market indices.
Historical precedent provides context but not a direct roadmap. The late 1990s–early 2000s technology capex cycle and the post‑2008 infrastructure waves offer analogues where fixed‑asset intensive sectors outperformed for multi‑year stretches; however, the current episode is shaped by different drivers — deglobalization, decarbonization and targeted industrial subsidies — which increase the probability of sustained above‑trend capex rather than a short, speculative spike.
Data Deep Dive
Three concrete data points underscore the developing story and its magnitude. First, the FT (27 Mar 2026) reports that chemical equities in Europe returned roughly +18% YTD through March 2026 versus a +5% return for the STOXX Europe 600 over the same window (FT, 27 Mar 2026). Second, the OECD national account releases show global manufacturing capital expenditure increased an estimated 8% in 2025 to about $1.05 trillion, with Asia accounting for ~45% of the total and Europe ~25% (OECD, 2025). Third, industry data compiled by World Semiconductor Trade Statistics project semiconductor industry capex at approximately $95 billion for 2026, representing a ~20% increase versus 2025 commitments (WSTS, 2026).
These figures translate into measurable changes in corporate fundamentals. On a trailing‑12‑month basis, chemical producers reported median operating margins expanding by roughly 120 basis points between Q4 2024 and Q4 2025, driven by higher realizations for specialty products and better asset utilization (company filings, FY2025). Balance sheets have also evolved: capital expenditure as a share of sales for the largest European chemical players moved from an average of 4.2% in 2023 to an estimated 5.6% in 2025, reflecting both maintenance and incremental capacity additions (company earnings releases, 2023–25). These shifts explain why equity markets have started to re‑price multiples for those businesses — investors are now attributing higher persistence to cash flows that were previously seen as cyclical.
Internal research at Fazen Capital corroborates nuance in the reallocation: while raw material cycles still inject volatility, the premium now accorded to firms with defensible feedstock access and proprietary chemistry patents has widened relative to broader materials peers. For further reading on how this influences sector allocations and factor risk, see our research hub on industrials and materials [topic](https://fazencapital.com/insights/en).
Sector Implications
The rotation into molecule‑heavy sectors has cascading implications across the supply chain. Producers of basic chemicals are recalibrating contract structures toward longer‑dated take‑or‑pay arrangements with downstream customers, reducing spot exposure and stabilizing revenue profiles. For midstream infrastructure providers — storage, logistics and ports specialized in chemical flows — the flow‑through is increased utilization and longer contract tenors, which in turn support lower idiosyncratic volatility for those equities relative to broader trade‑dependent peers.
Capital goods manufacturers, including those making reactors, wafer‑fabrication equipment and electrolyzers, stand to benefit from sustained order books. WFE (wafer fabrication equipment) order intake rose materially in 2025, and the pipeline into 2026 remains positive according to industry surveys (industry reports, 2025–26). This has secondary effects for industrial automation and engineering services, shifting some of the revenue growth away from purely domestic service firms back into manufacturing capex suppliers.
The service sector — software, media, consumer‑facing businesses — has not vanished but faces a recalibration of valuation multiples and investor expectations. Historically high growth multiples in parts of the service economy contracted as interest rates normalized and cyclical risk receded; the relative underperformance versus capex‑heavy sectors over the last year reflects both that macro adjustment and the new narrative that tangible assets can deliver durable returns in a less globalized world.
Risk Assessment
Key risks to the thesis are macro softness, commodity price reversals and policy inconsistency. A global growth shock would compress demand for chemicals and industrial capex, reversing recent gains; the chemical sector is particularly sensitive to GDP elasticity, with demand dropping faster in a recession than for many service segments. Commodity feedstock price volatility, notably naphtha and natural gas for chemicals, can erode margins quickly; for example, a 30% move higher in feedstock costs would materially compress typical integrated chemicals margins based on historical sensitivities (company disclosures, sensitivity tables).
Policy risk is non‑trivial. Industrial subsidies and tax incentives underpin much of the reshoring narrative; if governments pull back or if subsidy programs are litigated, the investment case for certain greenfield projects could evaporate. Execution risk at the company level — cost overruns, environmental permit delays, and technology missteps — remains elevated for large scale chemical and semiconductor projects whose timelines stretch multiple years.
Finally, valuation risk exists because some investors may have already priced a multi‑year outperformance into the more visible names. The current premium for integrated specialty chemical firms relative to their historical mean indicates a re‑rating that could be partly driven by sentiment; a measured, fundamentals‑based approach is therefore important to control downside concentration.
Fazen Capital Perspective
Fazen Capital views the current rotation as structural rather than purely cyclical, but with meaningful dispersion beneath headline sector moves. Our contrarian insight is that the most attractive opportunities are not the largest, most visible chemical conglomerates but a subset of mid‑cap specialty producers and materials suppliers that combine asset intensity with proprietary formulations and balanced contracts. These firms often trade at a discount to the majors despite exhibiting superior return on invested capital when new capacities are brought online. We also note that hedged, staged exposure via structured credit and private placement in project finance can capture upside from the capex cycle while mitigating the direct equity multiple expansion risk. For additional context on how to think about factor exposures and implementation, see our institutional insights [topic](https://fazencapital.com/insights/en).
Outlook
Looking ahead to the remainder of 2026 and into 2027, the durable elements of the molecule‑led reallocation are likely to persist if policy support remains intact and if real yields stabilize. If semiconductor and chemicals capex forecasts are realized — WSTS and OECD projections incorporated — order backlogs and multi‑year conversion cycles will continue to support elevated capacity utilization and improving margins for a subset of firms. However, investor due diligence should focus on balance‑sheet strength, feedstock procurement strategies and contractual cushioning against spot cycles.
The market will continue to bifurcate between firms that can monetize structural demand drivers (electrification, decarbonization, localized manufacturing) and those whose fortunes are tied to volatile commodity cycles. Active management, careful credit assessment and selective private markets participation are pragmatic ways for institutions to participate in this reallocation while controlling downside risk.
Bottom Line
The re‑pricing toward molecule‑centric, capital‑intensive sectors reflects real changes in policy and capex that are measurable and potentially durable; however, opportunities are heterogeneous and require disciplined, data‑driven selection. Disclaimer: This article is for informational purposes only and does not constitute investment advice.
FAQ
Q: How persistent could the outperformance of chemical and materials equities be? A: Persistence depends on policy continuity and capex execution; if OECD and industry capex projections materialize through 2027, multi‑year outperformance is plausible, but a recession or subsidy rollback would shorten the cycle.
Q: Are there ways to gain exposure without taking full equity risk? A: Institutions can consider private project finance, structured credit linked to long‑dated offtake contracts, or selective convertible instruments to capture capex upside while limiting multiple expansion risk; these implementations require careful counterparty and contract diligence.
Q: How does this rotation compare to historical capex cycles? A: Unlike the late‑1990s tech capex wave, the current cycle is more policy and supply‑chain driven (reshoring, decarbonization) with a higher share of government support, implying a different risk profile and potentially greater longevity.
Disclaimer: This article is for informational purposes only and does not constitute investment advice.
